Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma

Author(s): Priti Patel and Sandy Srinivas

Volume 6, Issue 3, 2011

Page: [181 - 188] Pages: 8

DOI: 10.2174/157488411797189442

Price: $65

Abstract

The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.

Keywords: Advanced renal cell carcinoma, targeted drugs, toxicity, mechanism, Hypertension, Proteinuria, Cardiotoxicity, Gastrointestinal Toxicities, Arterial Thrombosis, Hepatic Toxicities, Pulmonary Toxicity


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy